Intellia Therapeutics, Inc. (NTLA) Stock Analysis — Probabli.AI
AI-powered analysis for NTLA (Intellia Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $13.49 · Market cap: $1.6B · AI outlook: Bullish
Intellia Therapeutics offers significant upside due to its high revenue growth potential, recent clinical trial successes, strong industry partnerships, and positive analyst sentiment. Key risks include regulatory challenges and competition; however, the company's gene editing innovations and market adaptability position it favorably for substantial returns in the medium-to-long term.
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $10 / P50: $16 / P90: $25
- Intellia Therapeutics shows strong potential for price appreciation in the upcoming year, supported by recent positive trial results for NTLA-2001 and a promising revenue growth estimate. However, regulatory risks and…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $18 / P50: $35 / P90: $60
SWOT Highlights
- Strength: Promising gene editing pipeline
- Strength: High revenue growth expectations
- Risk: High negative earnings per share
- Risk: Significant dependency on regulatory approvals
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
20 Wall Street analysts rate NTLA a BUY with a mean price target of $20.45.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
NTLA forecast details · NTLA sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.